Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

被引:24
|
作者
Kanarek, Norma F. [1 ,2 ]
Kanarek, Marty S. [3 ,4 ]
Olatoye, Dare [5 ]
Carducci, Michael A. [6 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA
[4] Univ Wisconsin Madison, Nelson Inst Environm Studies, Madison, WI 53726 USA
[5] Johns Hopkins Sch Med, Baltimore, MD 21205 USA
[6] Johns Hopkins Sch Med, Dept Oncol Urol Oncol, Baltimore, MD USA
来源
TRIALS | 2012年 / 13卷
关键词
Justice; Beneficence; Respect for persons; Clinical trials; Clinical trial accrual; Prostate cancer; Barriers to clinical trials; Disparities; Framework; PROSTATE-SPECIFIC ANTIGEN; COMPREHENSIVE CANCER CENTER; INFORMED-CONSENT; RANDOMIZED-TRIALS; PATIENT INTEREST; DECISION-MAKING; BREAST-CANCER; WORKING GROUP; IMPACT; ENROLLMENT;
D O I
10.1186/1745-6215-13-237
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access. Methods: A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability. Results: We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant. Conclusions: The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Barriers to the participation of African-American patients with cancer in clinical trials - A pilot study
    Advani, AS
    Atkeson, B
    Brown, CL
    Peterson, BL
    Fish, L
    Johnson, JL
    Gockerman, JP
    Gautier, M
    CANCER, 2003, 97 (06) : 1499 - 1506
  • [32] Barriers to participation in clinical trials of rural older adult cancer survivors: A qualitative study
    Arana-Chicas, Evelyn
    Prisco, Laura M. Hincapie
    Sharma, Saloni
    Stauffer, Fiona
    Dauphin, Serge
    Ban-Hoefen, Makiko
    Navarette, Jaime
    Zittel, Jason
    Cupertino, Ana Paula
    Magnuson, Allison
    Mustian, Karen M.
    Mohile, Supriya G.
    JOURNAL OF RURAL HEALTH, 2025, 41 (01):
  • [33] Barriers and Facilitators to Participation in Clinical Trials Related to Familial Frontotemporal Dementia: A Qualitative Study
    Zammitt, David
    Brotherhood, Emilie V.
    Fearn, Caroline
    Greaves, Caroline
    Hayes, Ollie
    Harding, Emma
    Lykourgos, Madalena
    Rohrer, Jonathan D.
    Stott, Josh
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2024, 12 (11):
  • [34] Barriers to African American participation in clinical trials: A qualitative study of Central Brooklyn residents
    Johnson, Cicely K.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [35] TUBEROUS SCLEROSIS COMPLEX: CLINICAL SPECTRUM AND EPILEPSY: A RETROSPECTIVE CHART REVIEW STUDY
    Almobarak, Sulaiman
    Almuhaizea, Mohammad
    Abukhaled, Musaad
    Alyamani, Suad
    Dabbagh, Omar
    Chedrawi, Aziza
    Khan, Sameena
    Aldhalaan, Hesham
    TRANSLATIONAL NEUROSCIENCE, 2018, 9 (01) : 154 - 160
  • [36] Improving African American women?s engagement in clinical research: A systematic review of barriers to participation in clinical trials
    Le, Daisy
    Ozbeki, Hanna
    Salazar, Stefanie
    Berl, Madison
    Turner, Monique Mitchell
    Price, Olga Acosta
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2022, 114 (03) : 324 - 339
  • [37] Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews
    Rodriguez-Torres, Edgardo
    Gonzalez-Perez, Margarita M.
    Diaz-Perez, Clemente
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 23
  • [38] BARRIERS TO PARTICIPATION IN TRIALS OF CANCER: A SURVEY ON CLINICAL RESEARCH PERCEPTION
    Holtz, L.
    Cecilio, L.
    Julian, G.
    Minowa, E.
    VALUE IN HEALTH, 2015, 18 (07) : A810 - A810
  • [39] Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists
    Wong, Andrew R.
    Sun, Virginia
    George, Kevin
    Liu, Jennifer
    Padam, Simran
    Chen, Brandon A.
    George, Thomas
    Amini, Arya
    Li, Daneng
    Sedrak, Mina S.
    JCO ONCOLOGY PRACTICE, 2020, 16 (09) : 587 - +
  • [40] BARRIERS AND WILLINGNESS AMONG PHYSICIANS TOWARD PARTICIPATION IN CLINICAL TRIALS
    Alzahrani, Ahmed S.
    Alqahtani, Ali H.
    Alharthi, Sami S.
    Al Hussaini, Tawfiq M.
    Alshareif, Ahmed B.
    AlOtaibi, Abdullah F.
    AlWafi, Osama M.
    PHARMACOPHORE, 2020, 11 (03): : 117 - 123